NMRA
Neumora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
+3.05%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.61
From 52W high−83.61%
Volume1.01M
Market cap$110.54M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.61
From 52W high
−83.61%
Volume
1.01M
Market cap
$110.54M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
54.0
MomentumView details →
1D Return
+3.05%
YTD Return
−68.07%
SummaryUpdated Jun 1, 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Watertown, Massachusetts. The company went public in September 2023 and focuses on developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Originally incorporated as RBNC Therapeutics, Inc., the company changed its name to Neumora Therapeutics in October 2021. Neumora is currently advancing multiple clinical-stage programs targeting conditions that affect approximately 1.5 billion people worldwide, with its lead program being navacaprant for major depressive disorder.
Similar companies
Latest newsMore news →
NASDAQ, INC. notified Neumora Therapeutics that it was not in compliance with Listing Rule 5450(a)(1) because of its share price, giving the company until April 26, 2027, to regain compliance.5d agoPaul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.83d ago